GSK plc (GSK)
| Market Cap | 105.53B +30.0% |
| Revenue (ttm) | 43.29B +4.0% |
| Net Income | 7.70B +84.9% |
| EPS | 3.75 +86.6% |
| Shares Out | 4.02B |
| PE Ratio | 13.71 |
| Forward PE | 10.67 |
| Dividend | $1.77 (3.34%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 3,776,824 |
| Open | 53.80 |
| Previous Close | 53.66 |
| Day's Range | 52.45 - 53.80 |
| 52-Week Range | 35.45 - 61.70 |
| Beta | 0.29 |
| Analysts | Hold |
| Price Target | 56.63 (+6.67%) |
| Earnings Date | Jul 28, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for GSK stock is "Hold." The 12-month stock price target is $56.63, which is an increase of 6.67% from the latest price.
News
GSK upgraded to Hold from Reduce at HSBC
HSBC upgraded GSK (GSK) to Hold from Reduce with a price target of 1,860 GBp, up from 1,500 GBp. The key risk for the stock was a large patent cliff…
A Look at GSK PLC (GSK) After 4.6% Gain -- GF Value $43.94 vs Price $53.66
A Look at GSK PLC (GSK) After 4.6% Gain -- GF Value $43.94 vs Price $53.66
GSK (GSK) Has a Vaccines-and-Specialty-Medicines Mix Bigger Than a Patent-Expiry Debate
GSK (GSK) still gets pulled back into a familiar investor argument: how much of the equity story is simply a... The post GSK (GSK) Has a Vaccines-and-Specialty-Medicines Mix Bigger Than a Patent-Expir...
GSK Initiates Tender Offer for Nuvalent Shares
GSK Initiates Tender Offer for Nuvalent Shares
GSK announces commencement of tender offer to acquire Nuvalent
GSK (GSK) announced that Harmony Row Acquisition Co., a direct wholly-owned subsidiary of GlaxoSmithKline, which is an indirect wholly-owned subsidiary of GSK, has commenced a tender offer to purchase...
Spero: FDA Approves Utebzi, The First Oral Carbapenem For Complicated UTIs In Adults; Stock Up
(RTTNews) - GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the U.S. FDA has approved Utebzi (tebipenem pivoxil) as the first and only oral carbapenem antibiotic for adults with complicated...
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for ...
GSK Secures FDA Approval for Utebzi, First Oral Carbapenem for UTIs
GSK Secures FDA Approval for Utebzi, First Oral Carbapenem for UTIs
GSK Gains FDA Approval for New Oral Antibiotic Utebzi
GSK Gains FDA Approval for New Oral Antibiotic Utebzi
GSK, Spero Therapeutics announce FDA approval of Utebzi
GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the Food and Drug Administration has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections including ...
US FDA approves GSK's oral antibiotic for drug-resistant UTIs
The U.S. FDA has approved GSK's oral antibiotic to treat complicated urinary tract infections, the regulator said on Wednesday, giving patients a new treatment option against drug-resistant...
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK
Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...
GSK to Acquire Nuvalent for $10.6 Billion
GSK to Acquire Nuvalent for $10.6 Billion
Weekend Morning Brew: SpaceX IPO Soars; GSK Acquires Nuvalent
Weekend Morning Brew: SpaceX IPO Soars; GSK Acquires Nuvalent
GSK Gains Orphan Drug Designation for Momelotinib in VEXAS Syndrome Treatment
GSK Gains Orphan Drug Designation for Momelotinib in VEXAS Syndrome Treatment
GSK announces momelotinib granted ODD from U.S. FDA, EMA
GSK (GSK) announced that momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation, ODD, from the US Food and Drug Administration, FDA, and European…
GSK Receives FDA And EMA Orphan Drug Designations For Momelotinib In VEXAS Syndrome
(RTTNews) - GSK plc (GSK), a commercial-stage biopharmaceutical company, announced that it has received Orphan Drug Designation (ODD) for Ojjaara from the U.S. Food and Drug Administration (FDA) and E...
Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvalued
Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvalued
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
The sudden $10.6 billion acquisition of Nuvalent NASDAQ: NUVL by GSK NYSE: GSK violently shatters a lingering mergers and acquisitions (M&A) drought across the mid-cap biotechnology sector.
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZenec...
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuval...
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.
Nuvalent (NUVL) Soars Over 39% After GSK Acquisition Amid Mixed Market Trends
Nuvalent (NUVL) Soars Over 39% After GSK Acquisition Amid Mixed Market Trends
Market Today: GSK to Acquire Nuvalent in $10.6B Oncology Deal
Market Today: GSK to Acquire Nuvalent in $10.6B Oncology Deal